口服抑制剂-话题@MedSci

#口服抑制剂#

6篇内容 | 585人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1755489, encodeId=dda81e5548935, content=<a href='/topic/show?id=af2238208cc' target=_blank style='color:#2F92EE;'>#口服抑制剂#</a>, objectTitle=EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效, objectType=article, longId=195471, objectId=2fd71954e152, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fd71954e152, replyNumber=0, likeNumber=23, createdTime=2021-05-08, rootId=0, userName=neurosurgeon, userId=bbbd36920989, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fd71954e152, moduleTitle=EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fd71954e152)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755490, encodeId=30941e554905f, content=<a href='/topic/show?id=af2238208cc' target=_blank style='color:#2F92EE;'>#口服抑制剂#</a>, objectTitle=Clin Gastroenterology H:普雷米司特（磷酸二酯酶-4的口服抑制剂）在活动性溃疡性结肠炎患者中的疗效分析, objectType=article, longId=202100, objectId=8c0120210016, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0120210016, replyNumber=0, likeNumber=36, createdTime=2021-03-18, rootId=0, userName=neurosurgeon, userId=bbbd36920989, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0120210016, moduleTitle=Clin Gastroenterology H:普雷米司特（磷酸二酯酶-4的口服抑制剂）在活动性溃疡性结肠炎患者中的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c0120210016)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755487, encodeId=88e91e55487dd, content=<a href='/topic/show?id=af2238208cc' target=_blank style='color:#2F92EE;'>#口服抑制剂#</a>, objectTitle=Wnt口服抑制剂RXC004重新开始I / IIa期试验治疗晚期实体瘤, objectType=article, longId=158884, objectId=c80615888470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c80615888470, replyNumber=0, likeNumber=34, createdTime=2019-06-19, rootId=0, userName=neurosurgeon, userId=bbbd36920989, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c80615888470, moduleTitle=Wnt口服抑制剂RXC004重新开始I / IIa期试验治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c80615888470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755488, encodeId=80181e55488c8, content=<a href='/topic/show?id=af2238208cc' target=_blank style='color:#2F92EE;'>#口服抑制剂#</a>, objectTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, objectType=article, longId=166254, objectId=0b72166254e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b72166254e3, replyNumber=0, likeNumber=22, createdTime=2019-08-29, rootId=0, userName=neurosurgeon, userId=bbbd36920989, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b72166254e3, moduleTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b72166254e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755486, encodeId=e6b81e5548632, content=<a href='/topic/show?id=af2238208cc' target=_blank style='color:#2F92EE;'>#口服抑制剂#</a>, objectTitle=Blood：Duvelisib，一种新型的PI3K-δ和γ的口服抑制剂，对多种血液恶性肿瘤具有临床活性。, objectType=article, longId=122048, objectId=d42f12204853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d42f12204853, replyNumber=0, likeNumber=33, createdTime=2018-05-27, rootId=0, userName=neurosurgeon, userId=bbbd36920989, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d42f12204853, moduleTitle=Blood：Duvelisib，一种新型的PI3K-δ和γ的口服抑制剂，对多种血液恶性肿瘤具有临床活性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d42f12204853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1755485, encodeId=8f551e55485e1, content=<a href='/topic/show?id=af2238208cc' target=_blank style='color:#2F92EE;'>#口服抑制剂#</a>, objectTitle=CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤, objectType=article, longId=104994, objectId=4b3b104994b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b3b104994b6, replyNumber=0, likeNumber=32, createdTime=2018-03-05, rootId=0, userName=neurosurgeon, userId=bbbd36920989, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b3b104994b6, moduleTitle=CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b3b104994b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

口服抑制剂

2020-05-29

neurosurgeon (审核中...)

前往app查看评论内容

#口服抑制剂#

EULAR 2020：2期临床试验证明JAK1口服抑制剂Filgotinib在银屑病关节炎中的持久疗效

2021-05-08

neurosurgeon (审核中...)

前往app查看评论内容

#口服抑制剂#

Clin Gastroenterology H:普雷米司特（磷酸二酯酶-4的口服抑制剂）在活动性溃疡性结肠炎患者中的疗效分析

2021-03-18

neurosurgeon (审核中...)

前往app查看评论内容

#口服抑制剂#

Wnt口服抑制剂RXC004重新开始I / IIa期试验治疗晚期实体瘤

2019-06-19

neurosurgeon (审核中...)

前往app查看评论内容

#口服抑制剂#

辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果

2019-08-29

neurosurgeon (审核中...)

前往app查看评论内容

#口服抑制剂#

Blood：Duvelisib，一种新型的PI3K-δ和γ的口服抑制剂，对多种血液恶性肿瘤具有临床活性。

2018-05-27

neurosurgeon (审核中...)

前往app查看评论内容

#口服抑制剂#

CLIN CANCER RES：IDO1口服抑制剂治疗晚期实体肿瘤

2018-03-05

科室
- - 订阅+
  - 更多科室
工具
服务